摘要
应用干扰素ａ－２ｂ治疗慢性髓性白血病２５例，重点探讨（１）小剂量治疗是否有效；（２）疗效与慢性髓性白血病病期的关系；（３）能否诱导细胞遗传学或基因的缓解；（４）单用或联合用药疗效比较。结果提示，干扰素ａ－２ｂ应用於慢性期有较理想的疗效、完全血液学缓解达２６．３％，部分血液学缓解７３．７％，加速期疗效较差，与羟基脲或马利兰配合用药可提高疗效，我们近期观察２５例中，无一例达完全缓解，有待进一步观察和探索合理的治疗方案。
his paper reported the
therapeutic results of treatment of interferon a-2b in 25 cases of
chronicmyelogenousleukemia. What discussed here were:(1)whether it is
effective with low dose interferon therapy;2)the relationship between
curatibe efficacy and duration of disease;(3)Whether interferon can
indubce remission of cytogenetic and genetic ; (4 )compare the
results of single agent chemotherapy with that of combination
therapy.It was indicated that more satisfactory results could be
obtained in chronic phase of CML with interferon. Complete
hematologic remission rate was 26.3%, Partial hema-tyoiogic remission
rate was 73.7%. Curative efficacy was poor in accelerated phase,it
can be impro-ved when combined with hydroxyurea or busulfan . Because
no patient obtained complete remlssion in our 25 cases ,a appropriate
regimen is curreqtly under observation and investigation
出处
《北京医科大学学报》
CSCD
1994年第3期168-170,共3页
Journal of Peking University(Health Sciences)
关键词
干扰素
白血病
血液学缓解
Interferon
Chronic myelogenous leukemia ,Hematologyic remission
Complete rem i-ssion
